These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 11250604)

  • 1. [Preclinical evaluation of aromatase inhibitors antitumor activity].
    Auvray P; Bichat F; Genne P
    Bull Cancer; 2000 Dec; 87 Spec No():7-22. PubMed ID: 11250604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Aromatase inhibitors].
    Feutrie ML; Bonneterre J
    Bull Cancer; 1999 Oct; 86(10):821-7. PubMed ID: 10572233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of aromatase inhibitors in breast carcinoma.
    Santen RJ; Harvey HA
    Endocr Relat Cancer; 1999 Mar; 6(1):75-92. PubMed ID: 10732791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Aromatase inhibitors: a review of clinical trials].
    Kerbrat P; Lefeuvre C
    Bull Cancer; 2000 Dec; 87 Spec No():31-39. PubMed ID: 11250606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
    de Jong PC; Blijham GH
    Neth J Med; 1999 Aug; 55(2):50-8. PubMed ID: 10474272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Aromatase inhibitors: pharmacological aspects].
    de Crémoux P
    Bull Cancer; 2000 Dec; 87 Spec No():23-29. PubMed ID: 11250605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aromatase inhibitors: past, present and future in breast cancer therapy.
    Dutta U; Pant K
    Med Oncol; 2008; 25(2):113-24. PubMed ID: 17973095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The control and biological importance of intratumoural aromatase in breast cancer.
    Dowsett M; Lee K; Macaulay VM; Detre S; Rowlands M; Grimshaw R
    J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):145-50. PubMed ID: 8603035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroidal aromatase inhibitors in elderly patients.
    Bajetta E; Zilembo N; Bichisao E; Pozzi P; Toffolatti L
    Crit Rev Oncol Hematol; 2000 Feb; 33(2):137-42. PubMed ID: 10737375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A summary of second-line randomized studies of aromatase inhibitors.
    Buzdar AU
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):109-14. PubMed ID: 11850214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Long BJ; Jelovac D; Thiantanawat A; Brodie AM
    Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
    J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging role of aromatase inhibitors in the treatment of breast cancer.
    Harvey HA
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):32-5. PubMed ID: 9556789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibitors in metastatic breast cancer.
    Buzdar AU; Plourde PV; Hortobagyi GN
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):28-32. PubMed ID: 8824462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anastrozole: a new selective nonsteroidal aromatase inhibitor.
    Goss PE; Tye LM
    Oncology (Williston Park); 1997 Nov; 11(11):1697-703; discussion 1707-8. PubMed ID: 9394367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolving role of aromatase inhibitors in breast cancer.
    Mokbel K
    Int J Clin Oncol; 2002 Oct; 7(5):279-83. PubMed ID: 12402060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aromatase inhibitors come of age.
    Dowsett M
    Ann Oncol; 1997 Jul; 8(7):631-2. PubMed ID: 9296213
    [No Abstract]   [Full Text] [Related]  

  • 18. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy.
    Miller WR; Dixon JM
    Cancer Control; 2002; 9(2 Suppl):9-15. PubMed ID: 11965226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.
    Buzdar A; Howell A
    Clin Cancer Res; 2001 Sep; 7(9):2620-35. PubMed ID: 11555572
    [No Abstract]   [Full Text] [Related]  

  • 20. Are differences in the available aromatase inhibitors and inactivators significant?
    Johnson PE; Buzdar A
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4360s-4368s; discussion 4411s-4412s. PubMed ID: 11916226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.